SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Nvidia to build one of Israel's largest AI data centers

Kushner’s Affinity to pay $127M for additional Phoenix stake, securing $72M instant profit

High-tech must triumph over the kakistocracy

Sony Semiconductor Israel: “We will see more compute going into the edge”

Buzz

Most popular

Daily

Weekly

1

Orchid raises $36 million Seed round to automate enterprise identity security with AI

2

Mapping Israeli open source startups

3

Blockchain giant Chainalysis acquires Israeli startup Alterya in $150M deal

4

Israel faces AI crisis under new US export regulations

5

Israeli VCs find opportunity in adversity, betting big on 2025

Copaxone

4 stories about Copaxone

חברת ה תרופות טבע Teva

Teva’s Stock Drops After Approval of Copaxone Competitors

08.10.17|Lilach Baumer

A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer

Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug

מנכ"ל טבע החדש קור שולץ 2

New CEO to Break Teva’s Copaxone Habit

11.09.17|Sophie Shulman, Dror Reich

Troubled drugmaker says new CEO must work to quickly regain its financial credibility

תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian

The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016

Previous Articles